OMICS International

International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

 

Recommended Conferences for Insulin Therapy

Insulin Therapy


As per available reports about 4 Relevant Journals, 18 Conferences, 5 National Symposiums are presently dedicated exclusively Insulin Therapy and about 04 Open Access Articles are being published on Insulin Therapy.

Insulin therapy is the treatment of diabetes by administration of exogenous insulin. Insulin is used medically to treat some forms of diabetes mellitus. Patients with Type 1 diabetes mellitus depend on external insulin (most commonly injected subcutaneously) for their survival because the hormone is no longer produced internally. Patients with Type 2 diabetes mellitus insulin resistant have relatively low insulin production, or both; certain patients with Type 2 diabetes may eventually require insulin if other medications fail to control blood glucose levels adequately. 
The initial sources of insulin for clinical use in humans were cow, horse, pig or fish pancreases. Insulin from these sources is effective in humans as it is nearly identical to human insulin (three amino acid difference in bovine insulin, one amino acid difference in porcine). Differences in suitability of beef-, pork-, or fish-derived insulin for individual patients have historically been due to lower preparation purity resulting in allergic reactions to the presence of non-insulin substances. Insulin production from animal pancreases was widespread for decades, but very few patients today rely on insulin from animal sources, largely because few pharmaceutical companies sell it anymore. 

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Scope and Importance of Insulin Therapy

Randomised controlled trials have shown that maintenance of blood glucose levels below 110 mg/dl with intensive insulin therapy reduces mortality and morbidity of surgical and medical critically ill patients. An absolute reduction in the risk of death of 3-4 % is expected in intention-to-treat analysis, but the survival benefit increases when treatment is continued for at least a few days.

Old Content

Insulin therapy is the treatment of diabetes by administration of exogenous insulin. Insulin is used medically to treat some forms of diabetes mellitus. Patients with Type 1 diabetes mellitus depend on external insulin (most commonly injected subcutaneously) for their survival because the hormone is no longer produced internally. Patients with Type 2 diabetes mellitus insulin resistant have relatively low insulin production, or both; certain patients with Type 2 diabetes may eventually require insulin if other medications fail to control blood glucose levels adequately.

The initial sources of insulin for clinical use in humans were cow, horse, pig or fish pancreases. Insulin from these sources is effective in humans as it is nearly identical to human insulin (three amino acid difference in bovine insulin, one amino acid difference in porcine). Differences in suitability of beef-, pork-, or fish-derived insulin for individual patients have historically been due to lower preparation purity resulting in allergic reactions to the presence of non-insulin substances. Insulin production from animal pancreases was widespread for decades, but very few patients today rely on insulin from animal sources, largely because few pharmaceutical companies sell it anymore.

Eli Lilly marketed the first such insulin, Humulin, in 1982. Humulin was the first medication produced using modern genetic engineering techniques in which actual human DNA is inserted into a host cell (E. coli in this case). The host cells are then allowed to grow and reproduce normally, and due to the inserted human DNA, they produce a synthetic version of human insulin. However, the clinical preparations prepared from such insulin differ from endogenous human insulin in several important respects; an example is the absence of C-peptide which has in recent years been shown to have systemic effects itself. Genentech developed the technique Lilly used to produce Humulin, although the company never commercially marketed the product themselves. Novo Nordisk has also developed genetically engineered insulin independently using a yeast process. According to a survey that the International Diabetes Federation conducted in 2002 on the access to and availability of insulin in its member countries, approximately 70% of the insulin that is currently sold in the world is recombinant, biosynthetic 'human' insulin. A majority of insulin used clinically today is produced this way, although the clinical evidence has provided conflicting evidence on whether this insulin is any less likely to produce an allergic reaction. Adverse reactions have been reported, these include loss of warning signs that sufferers may slip into a coma through hypoglycemia, convulsions, memory lapse and loss of concentration.

Market Analysis

The global human insulin market crossed $23 billion in 2013 and is poised to grow at a high double-digit CAGR from 2014 to 2019.The market is segmented based on products, and types of insulin. Based on products, the global human insulin market is segmented into biologics and biobetters, and biosimilars/biogenerics. Human insulin market is also segmented into traditional and modern human insulin. Of these, modern human insulin and biosimilarswill be the fastest-growing market in the next five years.The major factors propelling this growth are cost effective treatment offered while using modern human insulin and low price of biosimilars/biogeneric drugs of human insulin thereby stimulating the demand for biosimilar human insulin products.

List of best International Conferences:

  1. 4th Nephrology Conference
    September 14-16, 2015, USA
  2. 3rd Endocrinology  Conference
    November  02-04,  2015, USA
  3. 11th Targeting  Diabetes  Conference
    October  17-19,  2016, Malaysia
  4. 6th Endocrinology  Conference
    November  28-30,  2016;  USA
  5. 6th Diabetes Conference
    November  02-04,  2015, UAE
  6. 8th Euro  Diabetes  Conference
    November  03-05,  2015, Spain
  7. 10th European  Diabetes  Conference
    July  14-16,  2016, UK
  8. 7th Indo Diabetes Conference
    November  23-25,  2015, India
  9. Thyroid Disorders  and treatment Conference
    February 29-March 02, 2016,  USA
  10. 9th Diabetologists Conference
    June 06-08, 2016, USA. 
  11. 2nd  Hormones  and  Steroids  Conference
    June  23-25,  2016, USA
  12. 11th Asia  Pacific  Diabetes  Conference
    July  11-13,  2016, Australia
  13. 12th Diabetes  Conference
    September  29-October  1,  2016, Canada
  14. 13th Diabetes  Conference 
    August  08-10,  2016, UK
  15. Metabolic Syndrome Conference
    October  20-22,  2016, UAE 
  16. International conference advanced in diabetes and insulin therapy
  17. Advances in Diabetes and Insulin Therapy 6th International Conference 2014 (ADiT 2014) 
  18. 6th International Conference on Advances in Diabetes & Insulin Therapy
  19. 7th International Conference on Advanced Technologies and treatment for diabetes
  20. 20th National Congress for People with Diabetes

Diabetes Societies

  1. American Diabetes Association
  2. Diabetes India Association
  3. Austrian Diabetes Association
  4. Flemish Diabetes Association
  5. Association of Juvenile Diabetes
  6. Canadian Diabetes Association
  7. Juvenile Diabetes Foundation of Chile
  8. Diabetological Colombian Federation
  9. Croatian Diabetes Association
  10. Union of Diabetics of Czech Republic
  11. Estonian Diabetes Association
  12. Finnish Diabetes Association German Diabetes Union
  13. Hellenic Diabetes Association
  14. Hong Kong Diabetes Federation
  15. Icelandic Diabetic Association
  16. Diabetic Association of India
  17. Diabetes Federation of Ireland
  18. The Diabetes Association (Italy) 
  19. Japan Diabetes Society
  20. Korean Diabetes Association

Companies 

  1. Orban Biotech
  2. LLC Novo Nordisk
  3. Cisbio Bioassays
  4. SemBioSys
  5. Ceres Chemical Co.
  6. Eli Lilly and Company
  7. signum Biosciences
  8. GlaxoSmithKline plc
  9. Proteome Sciences
  10. Centerchem Inc.
  11. Johnson & Johnson Services
  12. Vitamix
  13. Pharmed OUT.ORG
  14. Treeline
  15. Whole Foods
  16. Generic Drug
  17. Pacific BioLabs
  18. Crystal Chem

 

This page will be updated regularly.

This page was last updated on 11th Sep, 2015

Conferenceseries Destinations

Contact Us

Medical Conferences
Jessie Grace
jessie.grace@conferenceseries.com
1-702-508-5200 Ext:8031, 8041

Pharmaceutical Conferences
Badoni Victor
badoni.victor@conferenceseries.com
1-702-508-5200 Ext:8045, 8047

Immunology & Microbiology Conferences
Walker Smith
walker.smith@conferenceseries.com
1-702-508-5200 Ext:8031

Cancer Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Nursing and Healthcare Conferences
Jennifer Leny
jennifer.leny@conferenceseries.com
1-702-508-5200 Ext:8044

Diabetes Conferences
Stanley knight
stanley.knight@conferenceseries.com
1-702-508-5200 Ext:8040

Neuroscience Conferences
Sandeep Kumar
sandeep@conferenceseries.com
1-702-508-5200 Ext:8034

Dental Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Clinical and Biochemistry Conferences
Rohit Casper
rohit.casper@conferenceseries.com
1-702-508-5200 Ext:8033

Biotechnology Conferences
Ravi Vittal
ravi.vittal@conferenceseries.com
1-702-508-5200 Ext:8031, 8037

Material Science Conferences
Lucy Grey
lucygrey@conferenceseries.com
1-702-508-5200 Ext:8035

Genetics & Mol Biology Conferences
Stephen Bruce
stephen.bruce@conferenceseries.com
1-702-508-5200 Ext:8038

Engineering Conferences
Dolly A
dolly@conferenceseries.com
+1-702-508-5200 Ext:8051

Program Enquiries
Symposia/Workshops
Sponsorships
Media Partners | Advertising